Valvular heart diseaseAnalysis of 150 Patients With Carcinoid Syndrome Seen in a Single Year at One Institution in the First Decade of the Twenty-First Century
Section snippets
Methods and Results
One hundred fifty consecutive patients with histologically confirmed carcinoid tumors of midgut origin who had carcinoid syndrome were prospectively enrolled over a 12-month period from April 2006 to April 2007. The Neuroendocrine Tumour Unit at the Royal Free Hospital in London is a large, tertiary referral center for the management of neuroendocrine tumors. The unit has >800 patients with neuroendocrine tumors under active follow-up, including >150 patients with carcinoid tumors of midgut
Discussion
The prevalence of CHD has decreased from that reported in previous decades (50% to 70%) to about 20% of all patients with carcinoid syndrome.1, 2 The reduction in the prevalence of CHD is most likely due to the introduction of modern antitumor therapies that may cause significant reductions in the production of tumor metabolites and may also control tumor growth. Most notable of these therapies are somatostatin analogues. These analogues control symptoms of carcinoid syndrome and also result in
Reference (10)
- et al.
Recommendations for evaluation of the severity of native valvular regurgitation with two dimensional and Doppler echocardiography
J Am Soc Echocardiogr
(2003) - et al.
The clinical management of neuroendocrine tumours with long acting repeatable(LAR) octreotide: comparison with standard subcutaneous octreotide therapy
Ann Oncol
(2001) - et al.
Intracardiac phonocardiography in tricuspid regurgitation: relation to clinical and angiographic findings
Am J Cardiol
(1981) - et al.
Clinical and echocardiographic comparison of patients with the carcinoid syndrome with and without carcinoid heart disease
Am J Cardiol
(1989) - et al.
Relationship of circulating vasoactive substances to ultrasound detectable cardiac abnormalities
Circulation
(1988)
Cited by (90)
Carcinoid heart disease: Pathophysiology, clinical features, prognosis and treatment
2023, Archives des Maladies du Coeur et des Vaisseaux - PratiqueGastroenteropancreatic Neuroendocrine Tumors
2022, Gastroenterology Clinics of North AmericaRecent Advances in the Diagnosis and Management of Carcinoid Syndrome
2022, Disease-a-MonthCardiac Imaging in Carcinoid Heart Disease
2021, JACC: Cardiovascular ImagingOutcomes of surgical treatment for carcinoid heart disease: A systematic review and meta-analysis
2021, Surgery (United States)Managing carcinoid heart disease in patients with neuroendocrine tumors
2021, Annales d'EndocrinologieCitation Excerpt :A systolic murmur heard best along the sternal border and increasing on inspiration is the main clinical finding. Additionally, jugular venous pressure (JVP) elevation with a prominent V wave, ascites and peripheral oedema may also be found on clinical examination [9]. Chromogranin-A (CgA) is a glycoprotein released by NET cells and is a general biochemical marker used both at diagnosis and during follow-up in various types of NET.